David A. Siegel Sensei Biotherapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 19,000 shares of SNSE stock, worth $11,780. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,000

Previous 19,000 -0.0%

Holding current value

$11,780

Previous $13,000 46.15%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.53 - $0.82 $212 - $328	-400 Reduced 2.06%	19,000 $13,000
Q3 2023 Nov 14, 2023	SELL	$0.75 - $1.32 $4,125 - $7,260	-5,500 Reduced 22.09%	19,400 $15,000
Q2 2023 Aug 14, 2023	SELL	$1.14 - $1.81 $1,595 - $2,534	-1,400 Reduced 5.32%	24,900 $28,000
Q1 2023 May 15, 2023	SELL	$1.31 - $1.7 $11,921 - $15,470	-9,100 Reduced 25.71%	26,300 $39,000
Q4 2022 Feb 14, 2023	SELL	$1.33 - $1.74 $3,325 - $4,350	-2,500 Reduced 6.6%	35,400 $52,000

Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.24 $5,440 - $7,168	-3,200 Reduced 7.79%	37,900 $59,000
Q2 2022 Aug 15, 2022	BUY	$1.49 - $2.3 $298 - $459	200 Added 0.49%	41,100 $93,000
Q1 2022 May 16, 2022	BUY	$2.22 - $6.07 $46,398 - $126,863	20,900 Added 104.5%	40,900 $94,000
Q4 2021 Feb 14, 2022	BUY	$4.85 - $10.48 $97,000 - $209,600	20,000 New	20,000 $116,000
Q3 2021 Nov 15, 2021	SELL	$6.89 - $11.99 $159,848 - $278,168	-23,200 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.1 - $15.14 $111,020 - $184,708	12,200 Added 110.91%	23,200 $226,000
Q1 2021 May 17, 2021	BUY	$12.04 - $22.75 $132,440 - $250,250	11,000 New	11,000 $160,000

Others Institutions Holding SNSE

# of Institutions

Shares Held

2.32M

Call Options Held

Put Options Held

View Full List

About Sensei Biotherapeutics, Inc.

Ticker SNSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,720,300
Market Cap $19M
Description
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...

More about SNSE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account